Výsledky vyhledávání - "Sumit Kumar Subudhi"

Randomized phase II study of olaparib (Ola) maintenance following cabazitaxel-carboplatin induction chemotherapy (CabCarb) in men with aggressive variant prostate cancer (AVPC)

Autor: Patrick Glen Pilié, Rebecca Slack Tidwell, Paul Vincent Viscuse, Sumit Kumar Subudhi, Paul Gettys Corn, Shi-Ming Tu, John C. Araujo, Amado J. Zurita, Jennifer Wang, Eleni Efstathiou, Jessica Deinert, Christopher Logothetis, Timothy C. Thompson, Ana Aparicio

Publikováno v: Journal of Clinical Oncology. 41:196-196

196 Background: An aggressive subset of prostate cancers (AVPC) respond poorly to androgen signaling inhibitors, have limited therapeutic options and a dismal prognosis. Preclinical models of AVPC display functional alterations in DNA damage response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6706fe0124e91f0ce45a4776c546450e
https://doi.org/10.1200/jco.2023.41.6_suppl.196

Zobrazit plný text záznamu

Evaluation of the aggressive variant prostate cancer molecular profile (AVPCm) in CLIA environments

Autor: Paul Vincent Viscuse, Miao Zhang, Prih Rohra, Rebecca Slack Tidwell, Colin C. Pritchard, Sumit Kumar Subudhi, Patrick Glen Pilié, Christopher Logothetis, Paul Gettys Corn, Ana Aparicio

Publikováno v: Journal of Clinical Oncology. 41:250-250

250 Background: 20-30% of prostate cancers respond poorly to androgen receptor (AR)-directed therapies and have an atypical, virulent course. The aggressive variant prostate cancers ( AVPC) encompass virulent androgen indifferent tumors and are chara

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::06e6d03dcb13ccdcd9b412a46845cbb6
https://doi.org/10.1200/jco.2023.41.6_suppl.250

Zobrazit plný text záznamu

A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio)

Autor: Andrew Warren Hahn, Rebecca Slack Tidwell, Whittney Thoman, Amer Abdulla, Efstratios Koutroumpakis, Ana Aparicio, Sumit Kumar Subudhi, Bilal Ahmed Siddiqui, Patrick Glen Pilié, Amado J. Zurita, Paul Gettys Corn, Andrew Leonard Laccetti, Bagi RP Jana, Karen Basen-Engquist, Christopher Logothetis

Publikováno v: Journal of Clinical Oncology. 41:TPS273-TPS273

TPS273 Background: Prostate cancer is a disease of older age, and there is significant overlap with age-related illnesses. Androgens play a critical role in prostate cancer but also have been linked to cardiovascular (CV) disease, metabolic syndrome,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3e2db46e05def9b3be6c398d019fce4
https://doi.org/10.1200/jco.2023.41.6_suppl.tps273

Zobrazit plný text záznamu

Phase I/II study of the selective PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and PTEN loss

Publikováno v: Journal of Clinical Oncology. 40:5052-5052

5052 Background: PTEN loss activates the PI3K/AKT signaling pathway, contributes to an immunosuppressive tumor microenvironment, resistance to androgen deprivation therapy and poor clinical outcome in pts with mCRPC. Treatment with anti-PD1 antibodie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e206e9bc68c73ecbe7e35a8a4a7028a6
https://doi.org/10.1200/jco.2022.40.16_suppl.5052

Zobrazit plný text záznamu

DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC

Publikováno v: Journal of Clinical Oncology. 40:5059-5059

5059 Background: Response to androgen signaling inhibitors is highly variable and dictates prognosis in castration resistant prostate cancer (CRPC). The development of effective combinations for CRPC has been hampered by the absence of biomarkers to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::837f04dc8407711e1ede68661f23fcdd
https://doi.org/10.1200/jco.2022.40.16_suppl.5059

Zobrazit plný text záznamu

Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC)

Autor: Andrew Warren Hahn, Xuemei Wang, Eleni Efstathiou, Hyunsoo Hwang, Amado J. Zurita, Nicholas Spetsieris, Myrto A Boukovala, Jennifer Wang, John C. Araujo, Patrick Glen Pilie, Bilal A. Siddiqui, Sumit Kumar Subudhi, Paul Gettys Corn, Ana Aparicio, Shi-Ming Tu, Christopher Logothetis

Publikováno v: Journal of Clinical Oncology. 40:135-135

135 Background: In pre-operative studies, a short duration of AA + LHRHa produced marked cytoreduction in a subset of men with high-risk prostate cancer (PCa). However, in M0HNPC, androgen signaling inhibition (ASI) is reserved for men with short PSA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b3820ed5df244cc214bdecd3ee2e05c
https://doi.org/10.1200/jco.2022.40.6_suppl.135

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání